Chimeric proteins can exceed the sum of their parts: implications for evolution and protein design

Robert K. Campbell, Elizabeth R. Bergert, Yanhong Wang, John C. Morris, William R. Moyle

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Chimeric analogs derived from pairs of homologous proteins routinely exhibit activities found in one or both parents. We describe chimeras of two glycoprotein hormones, human chorionic gonadotropin (hCG) and human follitropin (hFSH), that exhibit activity unique to a third family member, human thy-rotropin (hTSH). The results show that biological activity can be separated from hormone-specific amino acid residues. This is consistent with a model for the evolution of homologous ligand–receptor pairs involving gene duplication and the creation of inhibitory determinants that restrict binding. Disruption of these determinants can unmask activities characteristic of other members of a protein family. Combining portions of two ligands to create analogs with properties of a third family member can facilitate identifying key determinants of protein–protein interaction and may be a useful strategy for creating novel therapeutics. In the case of the glycoprotein hormones, this showed that two different hormone regions (i.e., the seat-belt and the intersubunit groove) appear to limit inappropriate contacts with receptors for other members of this family. These observations also have important caveats for chimera-based protein design because an unexpected gain of function may limit the therapeutic usefulness of some chimeras.

Original languageEnglish (US)
Pages (from-to)439-443
Number of pages5
JournalNature Biotechnology
Volume15
Issue number5
DOIs
StatePublished - 1997

Fingerprint

Hormones
Proteins
Glycoproteins
Human Follicle Stimulating Hormone
Seat Belts
Gene Duplication
Follicle Stimulating Hormone
Chorionic Gonadotropin
Bioactivity
Amino acids
Genes
Parents
Ligands
Amino Acids
Therapeutics

Keywords

  • Chimeric proteins
  • Evolution
  • Human chorionic gonadotropin
  • Protein-protein interactions
  • Thyrotropin

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Medicine(all)
  • Molecular Medicine
  • Biomedical Engineering
  • Applied Microbiology and Biotechnology

Cite this

Chimeric proteins can exceed the sum of their parts : implications for evolution and protein design. / Campbell, Robert K.; Bergert, Elizabeth R.; Wang, Yanhong; Morris, John C.; Moyle, William R.

In: Nature Biotechnology, Vol. 15, No. 5, 1997, p. 439-443.

Research output: Contribution to journalArticle

Campbell, Robert K. ; Bergert, Elizabeth R. ; Wang, Yanhong ; Morris, John C. ; Moyle, William R. / Chimeric proteins can exceed the sum of their parts : implications for evolution and protein design. In: Nature Biotechnology. 1997 ; Vol. 15, No. 5. pp. 439-443.
@article{453f4b8c34ee4224af2ccd68134e0ae0,
title = "Chimeric proteins can exceed the sum of their parts: implications for evolution and protein design",
abstract = "Chimeric analogs derived from pairs of homologous proteins routinely exhibit activities found in one or both parents. We describe chimeras of two glycoprotein hormones, human chorionic gonadotropin (hCG) and human follitropin (hFSH), that exhibit activity unique to a third family member, human thy-rotropin (hTSH). The results show that biological activity can be separated from hormone-specific amino acid residues. This is consistent with a model for the evolution of homologous ligand–receptor pairs involving gene duplication and the creation of inhibitory determinants that restrict binding. Disruption of these determinants can unmask activities characteristic of other members of a protein family. Combining portions of two ligands to create analogs with properties of a third family member can facilitate identifying key determinants of protein–protein interaction and may be a useful strategy for creating novel therapeutics. In the case of the glycoprotein hormones, this showed that two different hormone regions (i.e., the seat-belt and the intersubunit groove) appear to limit inappropriate contacts with receptors for other members of this family. These observations also have important caveats for chimera-based protein design because an unexpected gain of function may limit the therapeutic usefulness of some chimeras.",
keywords = "Chimeric proteins, Evolution, Human chorionic gonadotropin, Protein-protein interactions, Thyrotropin",
author = "Campbell, {Robert K.} and Bergert, {Elizabeth R.} and Yanhong Wang and Morris, {John C.} and Moyle, {William R.}",
year = "1997",
doi = "10.1038/nbt0597-439",
language = "English (US)",
volume = "15",
pages = "439--443",
journal = "Biotechnology",
issn = "1087-0156",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Chimeric proteins can exceed the sum of their parts

T2 - implications for evolution and protein design

AU - Campbell, Robert K.

AU - Bergert, Elizabeth R.

AU - Wang, Yanhong

AU - Morris, John C.

AU - Moyle, William R.

PY - 1997

Y1 - 1997

N2 - Chimeric analogs derived from pairs of homologous proteins routinely exhibit activities found in one or both parents. We describe chimeras of two glycoprotein hormones, human chorionic gonadotropin (hCG) and human follitropin (hFSH), that exhibit activity unique to a third family member, human thy-rotropin (hTSH). The results show that biological activity can be separated from hormone-specific amino acid residues. This is consistent with a model for the evolution of homologous ligand–receptor pairs involving gene duplication and the creation of inhibitory determinants that restrict binding. Disruption of these determinants can unmask activities characteristic of other members of a protein family. Combining portions of two ligands to create analogs with properties of a third family member can facilitate identifying key determinants of protein–protein interaction and may be a useful strategy for creating novel therapeutics. In the case of the glycoprotein hormones, this showed that two different hormone regions (i.e., the seat-belt and the intersubunit groove) appear to limit inappropriate contacts with receptors for other members of this family. These observations also have important caveats for chimera-based protein design because an unexpected gain of function may limit the therapeutic usefulness of some chimeras.

AB - Chimeric analogs derived from pairs of homologous proteins routinely exhibit activities found in one or both parents. We describe chimeras of two glycoprotein hormones, human chorionic gonadotropin (hCG) and human follitropin (hFSH), that exhibit activity unique to a third family member, human thy-rotropin (hTSH). The results show that biological activity can be separated from hormone-specific amino acid residues. This is consistent with a model for the evolution of homologous ligand–receptor pairs involving gene duplication and the creation of inhibitory determinants that restrict binding. Disruption of these determinants can unmask activities characteristic of other members of a protein family. Combining portions of two ligands to create analogs with properties of a third family member can facilitate identifying key determinants of protein–protein interaction and may be a useful strategy for creating novel therapeutics. In the case of the glycoprotein hormones, this showed that two different hormone regions (i.e., the seat-belt and the intersubunit groove) appear to limit inappropriate contacts with receptors for other members of this family. These observations also have important caveats for chimera-based protein design because an unexpected gain of function may limit the therapeutic usefulness of some chimeras.

KW - Chimeric proteins

KW - Evolution

KW - Human chorionic gonadotropin

KW - Protein-protein interactions

KW - Thyrotropin

UR - http://www.scopus.com/inward/record.url?scp=0031003340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031003340&partnerID=8YFLogxK

U2 - 10.1038/nbt0597-439

DO - 10.1038/nbt0597-439

M3 - Article

C2 - 9131622

AN - SCOPUS:0031003340

VL - 15

SP - 439

EP - 443

JO - Biotechnology

JF - Biotechnology

SN - 1087-0156

IS - 5

ER -